While the MedicalXpress report highlights a doubling of U.S. postpartum depression rates from 9.4% to 19% between 2010 and 2021 per a JAMA Network Open study, this observational analysis of insurance claims data (large sample but prone to detection bias from increased screening awareness rather than true incidence rise) underplays how the baby blues—experienced by roughly 80% of mothers due to hormonal shifts—rarely progresses to clinical depression, a distinction Payne correctly notes but which lacks integration with RCT evidence on treatments. Missed in coverage is the 2023 Zurzuvae approval, backed by two phase 3 RCTs showing rapid symptom relief in moderate-to-severe cases versus placebo, contrasting with common SSRIs like sertraline that have mixed observational follow-up data on bonding outcomes. Emotional stakes for new mothers hinge on recognizing when transient sadness evolves into impairing despair, guilt, or suicidal ideation that disrupts infant attachment, a pattern amplified by genetic vulnerabilities not addressed in basic questionnaires. Synthesizing this with a 2022 meta-analysis in The Lancet Psychiatry (observational pooling across 58 studies, n>2 million, no major conflicts) underscores that untreated PPD elevates suicide risk and long-term child developmental issues, urging family support and sleep prioritization alongside medication.